Patent directory · USPTO A61K / A61P
Patents matching “s1”
59 pharma patents match "s1" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 59 pharmaceutical patents matching "s1" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
WO 2025202022
INHIBITEURS DE L'INTERACTION ENTRE RAS ET SOS1 À BASE DE QUINAZOLINE, MACROCYCLIQUES ET ANTICANCÉREUX
granted -
US 12409167
Pharmaceutical combination comprising a selective S1P1 receptor agonist
granted -
US 12336980
Dosing regimen for a selective S1P1 receptor agonist
granted -
US 12221610
RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
granted -
US 12202822
Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
granted -
US 12178861
Stabilized liquid and lyophilized ADAMTS13 formulations
granted -
US 12156903
Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
granted -
US 11958849
GLS1 inhibitors for treating disease
granted -
US 11918638
Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts
granted -
US 11779635
Subcutaneous administration of ADAMTS13
granted -
US 11739309
CRISPR-Cas12J effector polypeptides and methods of use thereof
granted -
US 11713462
Modulation of GYS1 expression
granted -
US 11713313
GLS1 inhibitors for treating disease
granted -
US 11661593
Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
granted -
US 11564979
Stabilized liquid and lyophilized ADAMTS13 formulations
granted -
US 11512078
Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
granted -
US 11472772
S1P3 antagonists
granted -
US 11370786
GLS1 inhibitors for treating disease
granted -
US 2022169620
SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS
granted -
US 11261444
Organic compositions to treat EPAS1-related diseases
granted -
US 11254666
Compound as GLS1 inhibitor
granted -
US 11236339
Modulation of GYS1 expression
granted -
US 11230544
Substituted 1,3,4-thiadiazoles as GLS1 inhibitors
granted -
US 11191818
Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
granted